Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05231122CT.gov Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | — | Recruiting | — | — | — |
NCT03329950CT.gov A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Peritoneal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cdx 1140 (this asset) | Roswell Park Cancer Institute | P2 | CCC · 52 |
| Cis-Diamminedichloroplatinum Ii | GOG Foundation | P3 | BBB |
| Carboplatin | University of Washington | P3 | BBB |
| Nogitecan | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BBB |
| Adriamycin | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BBB |
| Pegfilgrastim | TORL Biotherapeutics, LLC | P2/3 | BBB |
| Nivestim | Roswell Park Cancer Institute | P2 | BBB |
| Durvalumab | National Cancer Institute (NCI) | P2 | BB |
| Mirvetuximab Soravtansine | AbbVie | P3 | BB |
+42 more in the Primary Peritoneal Carcinoma cohort
Other indications for Cdx 1140
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | CCC · 51 |
| Endometrial Serous Adenocarcinoma | — | P2 | CCC · 51 |
| Ovarian Clear Cell Adenocarcinoma | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cdx 1140 in Primary Peritoneal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cdx-1140-primary-peritoneal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →